Based on the insights from the recent earnings call transcript, the company AmerisourceBergen has shown positive performance in the first quarter of fiscal 2017. Key highlights include a 4% increase in revenues to $38.2 billion, with strong contributions from the pharmaceutical distribution segment and the ABSG specialty business. The adjusted gross profit increased by 1% to $1.1 billion, and operating expenses were virtually flat compared to last year. Adjusted operating income was $486 million, up 2%, and adjusted diluted EPS increased by 7% to $1.36. The company also reported a positive outlook for fiscal '17, with adjusted EPS guidance raised to a new range of $5.72 to $5.92, reflecting growth of 2% to 5% versus the previous fiscal year.

The pharmaceutical distribution segment saw total revenues of $36.6 billion, up 4%, with strong performance in the retail customer segment and ABSG specialty business. Segment operating income was $374 million, down 2%, primarily due to contract renewals and generic deflation. The other segment, which includes Consulting Services, World Courier, and MWI Animal Health, reported operating income of $112 million, with a growth rate of 17%.

The company faced challenges with negative free cash flow of $570 million in the December quarter, but expects a positive free cash flow in the March quarter. The company also reaffirmed its guidance for adjusted net income and CapEx.

The company's fiscal '17 expectations were updated, with strong revenue growth anticipated, and the adjusted EPS range maintained with a focus on managing costs and capital deployment. The company's assumptions for pharmaceutical drug pricing environment, including generic and brand drug pricing, were also discussed in detail.

Overall, based on the positive performance and outlook for fiscal '17, it appears that AmerisourceBergen is in a strong position for future growth and shareholder value creation. As a financial analyst, I would adopt an 'overweight' investment stance for the company, considering its strong revenue growth, focus on cost management, and positive outlook for EPS growth.